trending Market Intelligence /marketintelligence/en/news-insights/trending/59KTLDk-DEnRxPpsSHkfBg2 content esgSubNav
In This List

Endo litigation against US FDA halted due to government shutdown

Blog

Insight Weekly: Ukraine war impact on mining; US bank growth slowdown; cloud computing headwinds

Blog

Insight Weekly: Cryptocurrency's growth; green bond market outlook; coal investors' windfall

Blog

Global M&A By the Numbers: Q1 2022

Blog

Insight Weekly: Challenges for European banks; Japan's IPO slowdown; carmakers' supply woes


Endo litigation against US FDA halted due to government shutdown

Endo International PLC said its lawsuit against the U.S. Food and Drug Administration will remain halted while the ongoing partial shutdown of the government remains in place.

The litigation challenges the FDA's authorization of the bulk compounding of drugs, the process of combining, mixing or altering ingredients by a licensed pharmacist to produce a medication tailored to the specific needs of a patient.

Endo is accusing the regulator of improperly authorizing the bulk compounding of hundreds of drugs, including "essentially a copy" of its blood-pressure drug Vasostrict, according to Reuters.

The FDA was supposed to make a determination by Dec. 31, before the partial government shutdown took place, on the inclusion of vasopressin, the active ingredient in Vasostrict, in the list of medicines that can be bulk compounded.